Tocilizumab for refractory post-COVID-19 pansclerotic morphea
- PMID: 38078570
- DOI: 10.1111/jdv.19692
Tocilizumab for refractory post-COVID-19 pansclerotic morphea
References
REFERENCES
-
- da Silva SJR, do Nascimento JCF, Germano Mendes RP, Guarines KM, Targino Alves da Silva C, da Silva PG, et al. Two years into the COVID‐19 pandemic: lessons learned. ACS Infect Dis. 2022;8(9):1758–1814.
-
- Lotfi Z, Haghighi A, Akbarzadehpasha A, Mozafarpoor S, Goodarzi A. Pansclerotic morphea following COVID‐19: a case report and review of literature on rheumatologic and non‐rheumatologic dermatologic immune‐mediated disorders induced by SARS‐CoV‐2. Front Med (Lausanne). 2021;8:728411.
-
- Voermans NC, Pillen S, de Jong EM, Creemers MC, Lammens M, van Alfen N. Morphea profunda presenting as a neuromuscular mimic. J Clin Neuromuscul Dis. 2008;9(4):407–414.
-
- Moreno‐Ajona D, Moreno‐Artero E, García de Eulate MR, Irimia P, España A. Facial solitary morphea profunda presenting with painful trigeminal neuropathy: a case report. Cephalalgia. 2019;39(4):564–568.
-
- Martini G, Campus S, Raffeiner B, Boscarol G, Meneghel A, Zulian F. Tocilizumab in two children with pansclerotic morphea: a hopeful therapy for refractory cases? Clin Exp Rheumatol. 2017;35 Suppl 106(4):211–213.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical